Co-development initiatives to advance next-generation workflows, accelerate adoption, and expand the role of AI within model-informed drug development Simulations Plus, Inc. (Nasdaq: SLP) ...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc.
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and ...
Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results